{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T23:40:48Z","timestamp":1787614848241,"version":"build-2736575974"},"reference-count":95,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,6,17]],"date-time":"2023-06-17T00:00:00Z","timestamp":1686960000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"S\u00e3o Paulo Research Foundation","award":["#2022\/04466-3"],"award-info":[{"award-number":["#2022\/04466-3"]}]},{"name":"S\u00e3o Paulo Research Foundation","award":["K08DE027119"],"award-info":[{"award-number":["K08DE027119"]}]},{"name":"USPHS","award":["#2022\/04466-3"],"award-info":[{"award-number":["#2022\/04466-3"]}]},{"name":"USPHS","award":["K08DE027119"],"award-info":[{"award-number":["K08DE027119"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Several cytokines with major biological functions in inflammatory diseases exert their functions through the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) signal transduction pathway. JAKs phosphorylate the cytoplasmic domain of the receptor, inducing the activation of its substrates, mainly the proteins known as STATs. STATs bind to these phosphorylated tyrosine residues and translocate from the cytoplasm to the nucleus, further regulating the transcription of several genes that regulate the inflammatory response. The JAK\/STAT signaling pathway plays a critical role in the pathogenesis of inflammatory diseases. There is also increasing evidence indicating that the persistent activation of the JAK\/STAT signaling pathway is related to several inflammatory bone (osteolytic) diseases. However, the specific mechanism remains to be clarified. JAK\/STAT signaling pathway inhibitors have gained major scientific interest to explore their potential in the prevention of the destruction of mineralized tissues in osteolytic diseases. Here, our review highlights the importance of the JAK\/STAT signaling pathway in inflammation-induced bone resorption and presents the results of clinical studies and experimental models of JAK inhibitors in osteolytic diseases.<\/jats:p>","DOI":"10.3390\/ijms241210290","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T01:31:14Z","timestamp":1687138274000},"page":"10290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["JAK\/STAT as a Potential Therapeutic Target for Osteolytic Diseases"],"prefix":"10.3390","volume":"24","author":[{"given":"Mariely A.","family":"Godoi","sequence":"first","affiliation":[{"name":"Department of Diagnosis and Surgery, School of Dentistry at Araraquara, UNESP, Araraquara 14801-385, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo C.","family":"Camilli","sequence":"additional","affiliation":[{"name":"Department of Diagnosis and Surgery, School of Dentistry at Araraquara, UNESP, Araraquara 14801-385, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen G. A.","family":"Gonzales","sequence":"additional","affiliation":[{"name":"Department of Diagnosis and Surgery, School of Dentistry at Araraquara, UNESP, Araraquara 14801-385, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit\u00f3ria B.","family":"Costa","sequence":"additional","affiliation":[{"name":"Department of Diagnosis and Surgery, School of Dentistry at Araraquara, UNESP, Araraquara 14801-385, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6425-4777","authenticated-orcid":false,"given":"Evangelos","family":"Papathanasiou","sequence":"additional","affiliation":[{"name":"Department of Periodontology, Tufts University School of Dental Medicine, Boston, MA 02111, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8053-4517","authenticated-orcid":false,"given":"F\u00e1bio R. M.","family":"Leite","sequence":"additional","affiliation":[{"name":"National Dental Research Institute Singapore, National Dental Centre, Singapore 168938, Singapore"},{"name":"Oral Health Academic Clinical Programme, Duke-NUS Medical School, Singapore 169857, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1297-9717","authenticated-orcid":false,"given":"Morgana R.","family":"Guimar\u00e3es-Stabili","sequence":"additional","affiliation":[{"name":"Department of Diagnosis and Surgery, School of Dentistry at Araraquara, UNESP, Araraquara 14801-385, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,6,17]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e23930","DOI":"10.4161\/jkst.23930","article-title":"JAK-STAT and Bone Metabolism","volume":"2","author":"Li","year":"2013","journal-title":"Jak-Stat"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"141","DOI":"10.4062\/biomolther.2011.19.2.141","article-title":"The Role of Jak\/STAT Pathways in Osteoclast Differentiation","volume":"19","author":"Lee","year":"2011","journal-title":"Biomol. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Damerau, A., Gaber, T., Ohrndorf, S., and Hoff, P. (2020). Jak\/Stat Activation: A General Mechanism for Bone Development, Homeostasis, and Regeneration. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239004"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/j.archoralbio.2011.03.022","article-title":"Expression of Suppressor of Cytokine Signaling 1 and 3 in Ligature-Induced Periodontitis in Rats","volume":"56","author":"Nogueira","year":"2011","journal-title":"Arch. Oral Biol."},{"key":"ref_5","first-page":"542","article-title":"JAKs and STATs in Immunoregulation and Immune-Mediated Disease","volume":"36","author":"Plenge","year":"2013","journal-title":"Immunity"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2020.1797280","article-title":"Guidelines for the Use and Interpretation of Assays for Monitoring Autophagy (4th Edition)1","volume":"17","author":"Klionsky","year":"2021","journal-title":"Autophagy"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"487","DOI":"10.2174\/1389450117666161207163054","article-title":"JAK\/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases","volume":"19","author":"Gao","year":"2017","journal-title":"Curr. Drug Targets"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.4049\/jimmunol.169.11.6610","article-title":"Rheumatoid Arthritis Synoviocyte Survival Is Dependent on Stat3","volume":"169","author":"Krause","year":"2002","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1089\/jir.2014.0012","article-title":"Involvement of the Janus Kinase\/Signal Transducer and Activator of Transcription Signaling Pathway in Multiple Sclerosis and the Animal Model of Experimental Autoimmune Encephalomyelitis","volume":"34","author":"Benveniste","year":"2014","journal-title":"J. Interf. Cytokine Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","article-title":"The Role of JAK\/STAT Signaling Pathway and Its Inhibitors in Diseases","volume":"80","author":"Xin","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.3899\/jrheum.120845","article-title":"RANKL\/OPG Ratio and DKK-1 Expression in Primary Osteoblastic Cultures from Osteoarthritic and Osteoporotic Subjects","volume":"40","author":"Corrado","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1007\/s11033-020-05910-9","article-title":"JAK\/STAT Pathway and Molecular Mechanism in Bone Remodeling","volume":"47","author":"Sanpaolo","year":"2020","journal-title":"Mol. Biol. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1080\/03008207.2017.1290085","article-title":"Osteoblast\u2013Osteoclast Interactions","volume":"59","author":"Chen","year":"2018","journal-title":"Connect. Tissue Res."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s10238-011-0170-5","article-title":"Expression of Vascular Endothelial Growth Factor in Normal, Osteoarthritic and Osteoporotic Osteoblasts","volume":"13","author":"Corrado","year":"2013","journal-title":"Clin. Exp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"891","DOI":"10.3892\/mmr.2013.1593","article-title":"Hwanggeumchal Sorghum Extract Enhances BMP7 and GH Signaling through the Activation of Jak2\/STAT5B in MC3T3-E1 Osteoblastic Cells","volume":"8","author":"Joung","year":"2013","journal-title":"Mol. Med. Rep."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2174\/138161207780249146","article-title":"The IGF-I Signaling Pathway","volume":"13","author":"Laviola","year":"2007","journal-title":"Curr. Pharm. Des."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.beem.2004.02.007","article-title":"Insulin-like Growth Factor I and Bone Mineral Density: Experience from Animal Models and Human Observational Studies","volume":"18","author":"Rosen","year":"2004","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1038\/sj.onc.1207131","article-title":"Coordinate Regulation of Cell Growth and Differentiation by TGF-\u03b2 Superfamily and Runx Proteins","volume":"23","author":"Miyazono","year":"2004","journal-title":"Oncogene"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1359\/JBMR.040701","article-title":"Growth Hormone Attenuates the Transcriptional Activity of Runx2 by Facilitating Its Physical Association with Stat3\u03b2","volume":"19","author":"Ziros","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1152\/ajpendo.00592.2005","article-title":"Whole Genome Microarray Analysis of Growth Hormone-Induced Gene Expression in Bone: T-Box3, a Novel Transcription Factor, Regulates Osteoblast Proliferation","volume":"291","author":"Govoni","year":"2006","journal-title":"Am. J. Physiol.\u2014Endocrinol. Metab."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1126\/scitranslmed.aay4447","article-title":"JAK Inhibition Increases Bone Mass in Steady-State Conditions and Ameliorates Pathological Bone Loss by Stimulating Osteoblast Function","volume":"12","author":"Adam","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Gaber, T., Brinkman, A.C.K., Pienczikowski, J., Diesing, K., Damerau, A., Pfeiffenberger, M., Lang, A., Ohrndorf, S., Burmester, G.R., and Buttgereit, F. (2020). Impact of Janus Kinase Inhibition with Tofacitinib on Fundamental Processes of Bone Healing. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21030865"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"109095","DOI":"10.1016\/j.intimp.2022.109095","article-title":"Advance in Bone Destruction Participated by JAK\/STAT in Rheumatoid Arthritis and Therapeutic Effect of JAK\/STAT Inhibitors","volume":"111","author":"Hu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1515\/hsz-2018-0253","article-title":"Inhibition of JAK2\/STAT3 Signaling Suppresses Bone Marrow Stromal Cells Proliferation and Osteogenic Differentiation, and Impairs Bone Defect Healing","volume":"399","author":"Yu","year":"2018","journal-title":"Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Yari, S., Kikuta, J., Shigyo, H., Miyamoto, Y., Okuzaki, D., Furusawa, Y., Minoshima, M., Kikuchi, K., and Ishii, M. (2023). JAK Inhibition Ameliorates Bone Destruction by Simultaneously Targeting Mature Osteoclasts and Their Precursors. Inflamm. Regen., 43.","DOI":"10.1186\/s41232-023-00268-4"},{"key":"ref_26","unstructured":"Godoi, M.A., Camilli, A.C., Costa, V.B., Gonzales, K.G.A., Santos, W.V., and Guimar\u00e3es-Stabili, M.R. (2022, January 15\u201318). JAK Inhibition Reduces Bone Resorption and Inflammation in Experimentally Induced Periodontitis in Rats. Proceedings of the Europerio 10, Copenhagen, Denmark. manuscript in preparation."},{"key":"ref_27","first-page":"1","article-title":"CYT387, a JAK-Specific Inhibitor Impedes Osteoclast Activity and Oophorectomy-Induced Osteoporosis via Modulating RANKL and ROS Signaling Pathways","volume":"13","author":"Li","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1172\/JCI118432","article-title":"Detection of Receptors for Lnterleukin-6, Lnterleukin-11, Leukemia Inhibitory Factor, Oncostatin M, and Ciliary Neurotrophic Factor in Bone Marrow Stromal\/Osteoblastic Cells","volume":"97","author":"Bellido","year":"1996","journal-title":"J. Clin. Investig."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/jbmr.2612","article-title":"WHI-131 Promotes Osteoblast Differentiation and Prevents Osteoclast Formation and Resorption in Mice","volume":"31","author":"Cheon","year":"2016","journal-title":"J. Bone Miner. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1159\/000465455","article-title":"IL-6 Enhances Osteocyte-Mediated Osteoclastogenesis by Promoting JAK2 and RANKL Activity in Vitro","volume":"41","author":"Wu","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1084\/jem.183.6.2581","article-title":"The Role of Gp130-Mediated Signals in Osteoclast Development: Regulation of Interleukin 11 Production by Osteoblasts and Distribution of Its Receptor in Bone Marrow Cultures","volume":"183","author":"Romas","year":"1996","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.4049\/jimmunol.1601528","article-title":"IL-3 Differentially Regulates Membrane and Soluble RANKL in Osteoblasts through Metalloproteases and the JAK2\/STAT5 Pathway and Improves the RANKL\/OPG Ratio in Adult Mice","volume":"200","author":"Singh","year":"2018","journal-title":"J. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.4049\/jimmunol.1000015","article-title":"IL-3 Inhibits Human Osteoclastogenesis and Bone Resorption through Downregulation of c-Fms and Diverts the Cells to Dendritic Cell Lineage","volume":"185","author":"Gupta","year":"2010","journal-title":"J. Immunol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.bbrc.2012.01.074","article-title":"IL-3 Promotes Osteoblast Differentiation and Bone Formation in Human Mesenchymal Stem Cells","volume":"418","author":"Barhanpurkar","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1002\/art.27645","article-title":"Inhibition of T Cell-Dependent and RANKL-Dependent Osteoclastogenic Processes Associated with High Levels of Bone Mass in Interleukin-15 Receptor-Deficient Mice","volume":"62","author":"Djaafar","year":"2010","journal-title":"Arthritis Rheum."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-017-1249-5","article-title":"Mechanistic Rationales for Targeting Interleukin-17A in Spondyloarthritis","volume":"19","author":"Raychaudhuri","year":"2017","journal-title":"Arthritis Res. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-018-1582-3","article-title":"IL-17A Induces Osteoblast Differentiation by Activating JAK2\/STAT3 in Ankylosing Spondylitis","volume":"20","author":"Jo","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0092-8674(00)81166-6","article-title":"Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses","volume":"93","author":"Rodig","year":"1998","journal-title":"Cell"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejim.2019.05.022","article-title":"JAK Inhibitors in 2019, Synthetic Review in 10 Points","volume":"66","author":"Muller","year":"2019","journal-title":"Eur. J. Intern. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","article-title":"The Emerging Safety Profile of JAK Inhibitors in Rheumatic Disease","volume":"13","author":"Winthrop","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ecco-jcc\/jjy085","article-title":"Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-Severe Ulcerative Colitis: Results from a Randomised, Phase 2 Study","volume":"12","author":"Sands","year":"2018","journal-title":"J. Crohn\u2019s Colitis"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1016\/S0140-6736(18)32463-2","article-title":"Efficacy and Safety of Filgotinib, a Selective Janus Kinase 1 Inhibitor, in Patients with Active Ankylosing Spondylitis (TORTUGA): Results from a Randomised, Placebo-Controlled, Phase 2 Trial","volume":"392","author":"Baraliakos","year":"2018","journal-title":"Lancet"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2014-205847","article-title":"Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancies across the Rheumatoid Arthritis Clinical Development Programme","volume":"75","author":"Curtis","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1002\/art.38779","article-title":"Analysis of Infections and All-Cause Mortality in Phase II, Phase III, and Long-Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis","volume":"66","author":"Cohen","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1136\/annrheumdis-2015-207319","article-title":"Tuberculosis and Other Opportunistic Infections in Tofacitinib-Treated Patients with Rheumatoid Arthritis","volume":"75","author":"Winthrop","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/art.39761","article-title":"Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments","volume":"68","author":"Xie","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2147\/JIR.S219586","article-title":"Jak Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical Data","volume":"13","author":"Harrington","year":"2020","journal-title":"J. Inflamm. Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1007\/s40265-017-0835-9","article-title":"Tofacitinib: A Review in Rheumatoid Arthritis","volume":"77","author":"Dhillon","year":"2017","journal-title":"Drugs"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1002\/art.34329","article-title":"The JAK Inhibitor Tofacitinib Regulates Synovitis through Inhibition of Interferon-\u03b3 and Interleukin-17 Production by Human CD4+ T Cells","volume":"64","author":"Maeshima","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3899\/jrheum.130683","article-title":"Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-Label, Longterm Extension Studies","volume":"41","author":"Wollenhaupt","year":"2014","journal-title":"J. Rheumatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms","volume":"75","author":"Rudolph","year":"2015","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/rmdopen-2016-000262","article-title":"Efficacy of Tofacitinib Monotherapy in Methotrexate-Naive Patients with Early or Established Rheumatoid Arthritis","volume":"2","author":"Fleischmann","year":"2016","journal-title":"RMD Open"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jbspin.2019.12.003","article-title":"Efficacy of Baricitinib on Periodontal Inflammation in Patients with Rheumatoid Arthritis","volume":"87","author":"Mihailov","year":"2020","journal-title":"Jt. Bone Spine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1002\/art.34649","article-title":"JAK Inhibition with Tofacitinib Suppresses Arthritic Joint Structural Damage through Decreased RANKL Production","volume":"64","author":"Labranche","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.04.015","article-title":"Tofacitinib Attenuates Arthritis Manifestations and Reduces the Pathogenic CD4 T Cells in Adjuvant Arthritis Rats","volume":"184","author":"Gertel","year":"2017","journal-title":"Clin. Immunol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/acr.24709","article-title":"Identification of Distinct Disease Activity Trajectories in Methotrexate-Naive Patients With Rheumatoid Arthritis Receiving Tofacitinib Over Twenty-Four Months","volume":"74","author":"Bykerk","year":"2022","journal-title":"Arthritis Care Res."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1136\/annrheumdis-2021-eular.474","article-title":"Pos0653 Impact of Upadacitinib or Adalimumab As Initial Therapy on the Achievement of 48-Week Treatment Goals in Patients With Rheumatoid Arthritis and Inadequate Response To Methotrexate: Post Hoc Analysis of a Phase 3 Study","volume":"80","author":"Mysler","year":"2021","journal-title":"Ann. Rheum. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-021-02590-z","article-title":"Patient- and Physician-Reported Outcomes from Two Phase 3 Randomized Studies (RAJ3 and RAJ4) of Peficitinib (ASP015K) in Asian Patients with Rheumatoid Arthritis","volume":"23","author":"Tanaka","year":"2021","journal-title":"Arthritis Res. Ther."},{"key":"ref_60","first-page":"1","article-title":"Patient-Reported Outcomes of Upadacitinib versus Abatacept in Patients with Rheumatoid Arthritis and an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: 12- and 24-Week Results of a Phase 3 Trial","volume":"24","author":"Bergman","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/mr\/roac021","article-title":"Post Hoc Analysis of Clinical Characteristics of Patients with Radiographic Progression in a Japanese Phase 3 Trial of Peficitinib and Methotrexate Treatment (RAJ4)","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s12185-022-03299-8","article-title":"Novel Treatments for Myelofibrosis: Beyond JAK Inhibitors","volume":"115","author":"Tremblay","year":"2022","journal-title":"Int. J. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/leu.2010.289","article-title":"The Novel JAK Inhibitor AZD1480 Blocks STAT3 and FGFR3 Signaling, Resulting in Suppression of Human Myeloma Cell Growth and Survival","volume":"25","author":"Scuto","year":"2011","journal-title":"Leukemia"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5246","DOI":"10.1182\/blood.V122.21.5246.5246","article-title":"Activity Of a JAK1\/JAK2 Inhibitor In a Patient With KIT-Mutated Systemic Mastocytosis (SM) Associated With Myelofibrosis","volume":"122","author":"Santos","year":"2013","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000497246","article-title":"Osteolytic Lesions in Primary Myelofibrosis and Effect of Ruxolitinib Therapy: Report of a Case and Literature Review","volume":"63","author":"Bucelli","year":"2019","journal-title":"Chemotherapy"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0140-6736(22)02036-0","article-title":"Momelotinib versus Danazol in Symptomatic Patients with Anaemia and Myelofibrosis (MOMENTUM): Results from an International, Double-Blind, Randomised, Controlled, Phase 3 Study","volume":"401","author":"Verstovsek","year":"2023","journal-title":"Lancet"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/bjh.18207","article-title":"Safety and Efficacy of Fedratinib, a Selective Oral Inhibitor of Janus Kinase-2 (JAK2), in Patients with Myelofibrosis and Low Pretreatment Platelet Counts","volume":"198","author":"Harrison","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/ajh.26709","article-title":"Safety and Efficacy of Jaktinib in the Treatment of Janus Kinase Inhibitor-Na\u00efve Patients with Myelofibrosis: Results of a Phase II Trial","volume":"97","author":"Zhang","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1530\/JOE-19-0518","article-title":"JAK2\/STAT3 Regulates Estrogen-Related Senescence of Bone Marrow Stem Cells","volume":"245","author":"Wu","year":"2020","journal-title":"J. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1089\/rej.2019.2239","article-title":"MiR-151a-3p Promotes Postmenopausal Osteoporosis by Targeting SOCS5 and Activating JAK2\/STAT3 Signaling","volume":"23","author":"Fu","year":"2020","journal-title":"Rejuvenation Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-019-0062-y","article-title":"Effects of Tofacitinib on the Clinical Features of Periodontitis in Patients with Rheumatoid Arthritis: Two Case Reports","volume":"3","author":"Kobayashi","year":"2019","journal-title":"BMC Rheumatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1600-0757.2011.00425.x","article-title":"The Global Burden of Periodontal Disease: Towards Integration with Chronic Disease Prevention and Control","volume":"60","author":"Petersen","year":"2012","journal-title":"Periodontol. 2000"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"S173","DOI":"10.1002\/JPER.17-0721","article-title":"Periodontitis: Consensus Report of Workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions","volume":"89","author":"Papapanou","year":"2018","journal-title":"J. Periodontol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1177\/0022034520945209","article-title":"IL-1 Superfamily Members and Periodontal Diseases","volume":"99","author":"Papathanasiou","year":"2020","journal-title":"J. Dent. Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1007\/s00784-018-2755-9","article-title":"Systemic Administration of Curcumin or Piperine Enhances the Periodontal Repair: A Preliminary Study in Rats","volume":"23","author":"Curylofo","year":"2019","journal-title":"Clin. Oral Investig."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/jcpe.12935","article-title":"A New Classification Scheme for Periodontal and Peri-Implant Diseases and Conditions\u2014Introduction and Key Changes from the 1999 Classification","volume":"45","author":"Caton","year":"2018","journal-title":"J. Clin. Periodontol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1177\/0022034521995157","article-title":"Host Modulation and Treatment of Periodontal Disease","volume":"100","author":"Balta","year":"2021","journal-title":"J. Dent. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.lfs.2009.03.001","article-title":"Signaling Pathways Associated with the Expression of Inflammatory Mediators Activated during the Course of Two Models of Experimental Periodontitis","volume":"84","author":"Spolidorio","year":"2009","journal-title":"Life Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1177\/0022034516645332","article-title":"SOCS-3 Regulates Alveolar Bone Loss in Experimental Periodontitis","volume":"95","author":"Papathanasiou","year":"2016","journal-title":"J. Dent. Res."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"L\u00fc, L., Yakoumatos, L., Ren, J., Duan, X., Zhou, H., Gu, Z., Mohammed, M., Uriarte, S.M., Liang, S., and Scott, D.A. (2020). JAK3 Restrains Inflammatory Responses and Protects against Periodontal Disease through Wnt3a Signaling. FASEB J., 9120\u20139140.","DOI":"10.1096\/fj.201902697RR"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1600-0765.2007.00977.x","article-title":"Osteogenic Effect of Interleukin-11 and Synergism with Ascorbic Acid in Human Periodontal Ligament Cells","volume":"42","author":"Leon","year":"2007","journal-title":"J. Periodontal Res."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1177\/154405910808701002","article-title":"IL-6 Induces Osteoblastic Differentiation of Periodontal Ligament Cells","volume":"87","author":"Iwasaki","year":"2008","journal-title":"J. Dent. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"104495","DOI":"10.1016\/j.archoralbio.2019.104495","article-title":"Cyclic Tensile Force-Upregulated IL6 Increases MMP3 Expression by Human Periodontal Ligament Cells","volume":"107","author":"Tantilertanant","year":"2019","journal-title":"Arch. Oral Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1590\/S1678-77572012000200002","article-title":"Modulation of Host Cell Signaling Pathways as a Therapeutic Approach in Periodontal Disease","volume":"20","author":"Garlet","year":"2012","journal-title":"J. Appl. Oral Sci."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.beem.2018.05.005","article-title":"Paget\u2019s Disease of Bone","volume":"32","author":"Papapoulos","year":"2018","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Lane, N.E. (2006). Epidemiology, Etiology, and Diagnosis of Osteoporosis. Am. J. Obstet. Gynecol., 194.","DOI":"10.1016\/j.ajog.2005.08.047"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1007\/s00198-015-3234-7","article-title":"The Effect of 8 or 5 Years of Denosumab Treatment in Postmenopausal Women with Osteoporosis: Results from the FREEDOM Extension Study","volume":"26","author":"Papapoulos","year":"2015","journal-title":"Osteoporos. Int."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab Treatment in Postmenopausal Women with Osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1001\/jama.2017.21995","article-title":"Treatment of Osteoporosis","volume":"319","author":"Cotts","year":"2018","journal-title":"JAMA\u2014J. Am. Med. Assoc."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"116512","DOI":"10.1016\/j.bone.2022.116512","article-title":"Early Treatment of Osteopetrosis: Paradigm Shift to Marrow Cell Transplantation","volume":"164","author":"Teti","year":"2022","journal-title":"Bone"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrendo.2013.137","article-title":"Osteopetrosis: Genetics, Treatment and New Insights into Osteoclast Function","volume":"9","author":"Sobacchi","year":"2013","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Liu, C., Arnold, R., Henriques, G., and Djabali, K. (2019). Inhibition of JAK-STAT Signaling with Baricitinib Reduces Inflammation and Improves Cellular Homeostasis in Progeria Cells. Cells, 8.","DOI":"10.3390\/cells8101276"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT Pathway and Nociceptive Cytokine Signalling in Rheumatoid Arthritis and Psoriatic Arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41584-022-00764-w","article-title":"Effects of Targeted Therapies on Bone in Rheumatic and Musculoskeletal Diseases","volume":"18","author":"Raterman","year":"2022","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:55:42Z","timestamp":1760126142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/12\/10290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,17]]},"references-count":95,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,6]]}},"alternative-id":["ijms241210290"],"URL":"https:\/\/doi.org\/10.3390\/ijms241210290","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,17]]}}}